



AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA455) NICE GUIDANCE ISSUED JULY 2017

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

**Final Appraisal Recommendation
Advice No: 3615 – November 2015**

**Adalimumab (Humira[®]) 40 mg/0.8 ml solution for injection for
paediatric use**

Limited submission by AbbVie Ltd

Recommendation of AWMSG

Adalimumab (Humira[®]) is recommended as an option for restricted use within NHS Wales for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to, or are inappropriate candidates for, topical therapy and phototherapies. Prescribing should be restricted to clinical situations as specified within the National Institute for Health and Care Excellence (NICE) guidance for adults.

Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2571), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review every three years.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3615:
adalimumab (Humira[®]) 40 mg/0.8 ml solution for injection for paediatric use. November 2015.

